Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

1.

Living-related donor renal transplantation in HIV+ recipients using alemtuzumab preconditioning and steroid-free tacrolimus monotherapy: a single center preliminary experience.

Tan HP, Kaczorowski DJ, Basu A, Khan A, McCauley J, Marcos A, Fung JJ, Starzl TE, Shapiro R.

Transplantation. 2004 Dec 15;78(11):1683-8.

2.

Steroid-free tacrolimus monotherapy after pretransplantation thymoglobulin or Campath and laparoscopy in living donor renal transplantation.

Tan HP, Kaczorowski D, Basu A, McCauley J, Marcos A, Donaldson J, Unruh M, Randhawa P, Zeevi A, Shapiro R.

Transplant Proc. 2005 Dec;37(10):4235-40.

PMID:
16387087
3.

Living donor renal transplantation using alemtuzumab induction and tacrolimus monotherapy.

Tan HP, Kaczorowski DJ, Basu A, Unruh M, McCauley J, Wu C, Donaldson J, Dvorchik I, Kayler L, Marcos A, Randhawa P, Smetanka C, Starzl TE, Shapiro R.

Am J Transplant. 2006 Oct;6(10):2409-17. Epub 2006 Aug 4.

4.

Two hundred living donor kidney transplantations under alemtuzumab induction and tacrolimus monotherapy: 3-year follow-up.

Tan HP, Donaldson J, Basu A, Unruh M, Randhawa P, Sharma V, Morgan C, McCauley J, Wu C, Shah N, Zeevi A, Shapiro R.

Am J Transplant. 2009 Feb;9(2):355-66. doi: 10.1111/j.1600-6143.2008.02492.x. Epub 2008 Dec 15.

5.

Pediatric living donor kidney transplantation under alemtuzumab pretreatment and tacrolimus monotherapy: 4-year experience.

Tan HP, Donaldson J, Ellis D, Moritz ML, Basu A, Morgan C, Vats AN, Erkan E, Shapiro R.

Transplantation. 2008 Dec 27;86(12):1725-31. doi: 10.1097/TP.0b013e3181903da7.

PMID:
19104412
6.

Alemtuzumab pre-conditioning with tacrolimus monotherapy in pediatric renal transplantation.

Shapiro R, Ellis D, Tan HP, Moritz ML, Basu A, Vats AN, Kayler LK, Erkan E, McFeaters CG, James G, Grosso MJ, Zeevi A, Gray EA, Marcos A, Starzl TE.

Am J Transplant. 2007 Dec;7(12):2736-8. Epub 2007 Oct 1.

7.

Single dose of alemtuzumab induction with steroid-free maintenance immunosuppression in pancreas transplantation.

Uemura T, Ramprasad V, Matsushima K, Shike H, Valania T, Kwon O, Ghahramani N, Shah R, Farooq U, Khan A, Kadry Z.

Transplantation. 2011 Sep 27;92(6):678-85. doi: 10.1097/TP.0b013e31822b58be.

8.

Early outcomes in human lung transplantation with Thymoglobulin or Campath-1H for recipient pretreatment followed by posttransplant tacrolimus near-monotherapy.

McCurry KR, Iacono A, Zeevi A, Yousem S, Girnita A, Husain S, Zaldonis D, Johnson B, Hattler BG, Starzl TE.

J Thorac Cardiovasc Surg. 2005 Aug;130(2):528-37.

9.

Alemtuzumab preconditioning with tacrolimus monotherapy-the impact of serial monitoring for donor-specific antibody.

Shapiro R, Zeevi A, Basu A, Tan HP, Kayler LK, Blisard DM, Thai NL, Girnita AL, Randhawa PS, Gray EA, Marcos A, Starzl TE.

Transplantation. 2008 Apr 27;85(8):1125-32. doi: 10.1097/TP.0b013e31816a8a6d.

10.

Alemtuzumab (Campath-1H) and tacrolimus monotherapy after renal transplantation: results of a prospective randomized trial.

Margreiter R, Klempnauer J, Neuhaus P, Muehlbacher F, Boesmueller C, Calne RY.

Am J Transplant. 2008 Jul;8(7):1480-5. doi: 10.1111/j.1600-6143.2008.02273.x.

11.

Campath induction for kidney transplantation: report of 297 cases.

Ortiz J, Palma-Vargas J, Wright F, Bingaman A, Agha I, Rosenblatt S, Foster P.

Transplantation. 2008 Jun 15;85(11):1550-6. doi: 10.1097/TP.0b013e31816f60cf.

PMID:
18551058
12.

Use of alemtuzumab and tacrolimus monotherapy for cadaveric liver transplantation: with particular reference to hepatitis C virus.

Marcos A, Eghtesad B, Fung JJ, Fontes P, Patel K, Devera M, Marsh W, Gayowski T, Demetris AJ, Gray EA, Flynn B, Zeevi A, Murase N, Starzl TE.

Transplantation. 2004 Oct 15;78(7):966-71.

13.

Alemtuzumab induction in deceased donor kidney transplantation.

Shin M, Song SH, Kim JM, Kwon CH, Joh JW, Lee SK, Kim SJ.

Transplant Proc. 2011 Jul-Aug;43(6):2365-78. doi: 10.1016/j.transproceed.2011.05.032.

PMID:
21839271
14.

Kidney transplantation achievements in Mongolia.

Jambaljav L, Nyamsuren D, Byambadash B, Ganbold L.

Transplant Proc. 2010 Apr;42(3):791-2. doi: 10.1016/j.transproceed.2010.03.031.

PMID:
20430173
15.

Alemtuzumab (Campath 1H) induction with tacrolimus monotherapy is safe for high immunological risk renal transplantation.

Thomas PG, Woodside KJ, Lappin JA, Vaidya S, Rajaraman S, Gugliuzza KK.

Transplantation. 2007 Jun 15;83(11):1509-12.

PMID:
17565326
16.

Alemtuzumab induction with tacrolimus monotherapy in de novo renal transplantation.

Villanueva ME, Muñoz AS, Casasola CC, Africa JB, Danguilan RA, Ona ET.

Transplant Proc. 2008 Sep;40(7):2222-5. doi: 10.1016/j.transproceed.2008.06.037.

PMID:
18790198
17.

Kidney transplantation with minimized maintenance: alemtuzumab induction with tacrolimus monotherapy--an open label, randomized trial.

Chan K, Taube D, Roufosse C, Cook T, Brookes P, Goodall D, Galliford J, Cairns T, Dorling A, Duncan N, Hakim N, Palmer A, Papalois V, Warrens AN, Willicombe M, McLean AG.

Transplantation. 2011 Oct 15;92(7):774-80. doi: 10.1097/TP.0b013e31822ca7ca.

PMID:
21836540
18.

[Preliminary experience with Campath 1H induction combined with low-dose monotherapy of tacrolimus in small bowel transplantation].

Li YX, Li N, Ni XD, Li YS, Li M, Shen J, Li JS.

Zhonghua Wai Ke Za Zhi. 2009 Jun 1;47(11):810-3. Chinese.

PMID:
19961008
19.

Experience with Alemtuzumab (Campath-1H) as induction agent in renal transplantation followed by steroid-free immunosuppression.

Baez Y, Giron F, Niño-Murcia A, Rodríguez J, Salcedo S.

Transplant Proc. 2008 Apr;40(3):697-9. doi: 10.1016/j.transproceed.2008.02.026.

PMID:
18454990
20.

Alemtuzumab induction and tacrolimus monotherapy in pancreas transplantation: One- and two-year outcomes.

Thai NL, Khan A, Tom K, Blisard D, Basu A, Tan HP, Marcos A, Fung JJ, Starzl TE, Shapiro R.

Transplantation. 2006 Dec 27;82(12):1621-4.

Supplemental Content

Support Center